when should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease?
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

when should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease?

;D.D. Ivanov
oncology letters 2017 Vol. 6 pp. 31-35
182
ivanov2017pokiwhen

Abstract

International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus.

Keywords

diabetic kidney disease urology

Access

DOI:
10.22141/2307-1257.6.1.2017.93781
URL:
http://kidneys.zaslavsky.com.ua/article/view/93781

Citation

ID: 175029
Ref Key: ivanov2017pokiwhen
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
175029
Unique Identifier:
10.22141/2307-1257.6.1.2017.93781
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store